HEMO.LSE Hemogenyx Pharmaceuticals PLC

Healthcare Biotechnology London Exchange
6.40 GBX
Close of Nov 3, 2026
356.00 1,220
Market cap
GBX 44.1M
P/E
-
P/B
9.63x
ROE
-605.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is HEMO.LSE undervalued?

Graham number

The Graham number of Hemogenyx Pharmaceuticals PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hemogenyx Pharmaceuticals PLC fundamental analysis

No fundamental analysis for Hemogenyx Pharmaceuticals PLC yet.

Hemogenyx Pharmaceuticals PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specif…

Full company profile